Study to investigate safety, tolerability, pharmacodynamics and pharmacokinetic properties of BAY 63-2521 after dosing of a 2 mg tablet in 20 patients with Raynaud’s phenomenon (RP)

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

The primary objective of the study is to investigate the safety, tolerability and pharmacodynamics of a single oral dose of BAY 63-2521 administered in patients suffering from Raynaud’s phenomenon

Critère d'inclusion

Patients with 1° and 2° Raynaud’s phenomenon (RP)

Liens

euctr